Aktienanalyse zu Acadia Pharmaceuticals Inc. (ACAD)ACADAcadia Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc.is a biopharmaceutical company. The Company is focused on innovation that makes the difference for underserved neurological and rare disease communities around the world. Its commercial portfolio includes the first and only FDA-approved treatments for Parkinson's disease psychosis and Rett syndrome. It is also developing therapeutic advancements with diverse pipelines that include mid- to late-stage programs in Alzheimer's disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs that address other underserved patient needs. Its pipeline of product candidates includes Remlifanserin (formerly ACP-204), ACP-211, ACP-711, ACP-271, ACP-259, and Antisense Oligonucleotide (ASO) Program. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. DAYBUE (trofinetide) is developed for the treatment of Rett Syndrome. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

ACADIA Pharmaceuticals is a good buy right now due to its recent EU approval for DAYBU, which is expected to significantly boost revenues. The current price of $29.11 is below several analyst price targets, such as $38 from Deutsche Bank and $40 from Citi. Additionally, the company has a strong gross margin of 90.81% and a forward P/E ratio of 71.94, suggesting growth potential despite current volatility.

10 analysts cover ACAD: 8 rate it Buy, 2 Hold and 0 Sell. The average price target is 31.17.